Inhibikase Therapeutics, Inc. (IKT) › Operating Cash FlowInhibikase Therapeutics, Inc. (IKT) — Operating Cash FlowAnnual figures by period end, from SEC filings.2020-12-31: -$1.13M2021-12-31: -$14.30M2022-12-31: -$17.35M2023-12-31: -$18.09M2024-12-31: -$19.15M2025-12-31: -$27.79M-$27.79M2020-12-31Operating Cash Flow (USD)2025-12-31Period endedOperating Cash FlowChange YoYSource filing2025-12-31-$27.79M—2026-03-26From 2025-01-012024-12-31-$19.15M—2026-03-26From 2024-01-012023-12-31-$18.09M—2025-03-27From 2023-01-012022-12-31-$17.35M—2024-03-27From 2022-01-012021-12-31-$14.30M—2023-03-31From 2021-01-012020-12-31-$1.13M—2022-03-31From 2020-01-01Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)